Skip to main content

Table 3 Flow cytometry data for different phenotypic biomarkers from CD4 or CD8 T cells with absolute changes and fold-changes over baseline control samples at 3- (Table 3a) and 6-month (Table 3b) post ipilimumab with p-values for the differences shown

From: Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Biomarker n Median change * (Q1, Q3) Wilcoxon p-value Median foldchange * (Q1, Q3) Wilcoxon p-value
a. Statistical analysis of changes in biomarkers at 3 months
%-ICOS-CD4 25 13.00 (1.15, 20.69) <.0001 1.35 (0.23, 3.62) <.0001
%-ICOS-CD8 25 4.19 (2.07, 7.75) <.0001 2.90 (1.25, 6.72) <.0001
%-Ki67-CD4 24 3.62 (0.74, 6.94) <.0001 1.50 (0.18, 2.64) <.0001
%-Ki67-CD8 24 1.49 (−0.10, 4.86) 0.0009 0.54 (−0.03, 2.20) 0.0003
%-CCR7-CD8 25 −3.98 (−11.40, 1.30) 0.0122 −0.14 (−0.27, 0.04) 0.018
%-CD25-CD8 25 −1.60 (−5.68, -0.70) <.0001 −0.42 (−0.56, -0.25) <.0001
b. Statistical analysis of changes in biomarkers at 6 months
%-ICOS-CD4 37 9.45 (3.13, 14.57) <.0001 1.66 (0.70, 2.42) <.0001
%-ICOS-CD8 37 3.07 (1.62, 5.36) <.0001 1.34 (0.63, 3.30) <.0001
%-Ki67-CD4 35 2.33 (1.37, 6.97) <.0001 0.87 (0.29, 2.12) <.0001
%-Ki67-CD8 36 1.88 (0.13, 4.91) 0.0004 0.55 (0.04, 1.52) <.0001
%-Gata3-CD4 28 3.76 (0.28, 8.04) 0.0004 0.94 (−0.01, 1.62) <.0001
%-Gata3-CD8 28 2.07 (0.59, 4.02) 0.0006 0.59 (0.09, 1.23) <.0001
%-CCR7-CD4 37 −2.90 (−6.80, -0.40) 0.0017 −0.03 (−0.09, -0.01) 0.006
  1. *(Q1, Q3) are first and third interquartiles.